# Dying, Fast and Slow: The Ethics of Living Longer | Raiany Romanni-Klein | TEDxBoston Source: https://www.youtube.com/watch?v=kB1IFGYaYXo Recap page: https://rapidrecap.app/video/kB1IFGYaYXo Generated: 2026-01-27T17:31:43.354+00:00 --- ## Quick Overview Raiany Romanni-Klein argues that humanity must shift its focus from treating individual age-related diseases one by one toward tackling the underlying biology of aging to maximize healthspan and economic returns, citing the massive economic benefit of extending healthy life, which is currently undervalued compared to spending on treating late-stage diseases. **Key Points:** - Historically, most deaths were 'fast deaths' (infection, accidents, etc.), but since the 20th century, the majority of deaths are now 'slow deaths' from age-related diseases, like cardiovascular disease (killing nearly 1/3 globally). - In the US in 2025, average life expectancy is 79, but the average person receives their first chronic disease diagnosis around age 50, meaning about 29 years are spent in declining health. - Addressing aging itself offers massive economic returns; curing all cancers, for example, is projected to yield $80T in economic value to the US over decades, far exceeding the current NIH funding for the biology of aging ($500M vs $18B for other late-stage diseases). - The speaker proposes five potential solutions to slow death, including setting a maximum lifespan of 65 (which she deems unethical) and focusing on treating the diseases of aging one by one, noting that curing all cancers only adds about 2.5 years to life expectancy. - She champions fundamental research into aging biology, showing that slowing aging by just one year could result in a $3T annual gain to the US GDP. - The speaker points out that the current funding model for diseases like Alzheimer's is circular and based on urgency rather than impact, as research is funded because it's difficult and urgent, leading to a lack of focus on fundamental aging research. - If humans lived as long as some other species (like the Greenland Shark at 500 years) or could extend their productivity years, the economic gains would be enormous, potentially adding trillions to the US GDP. ![Screenshot at 00:27: A timeline graphic illustrating the shift from millennia dominated by 'fast deaths' \(blue, infection, accidents\) to the modern era dominated by 'slow deaths' \(pink, age-related diseases\) starting around the turn of the 20th century, highlighting the current focus of mortality.](https://ss.rapidrecap.app/screens/kB1IFGYaYXo/00-00-27.jpg) **Context:** Raiany Romanni-Klein, CEO of the Institute for Life and Technology, presents a TEDxBoston talk arguing for a paradigm shift in medical research funding from treating individual age-related diseases to targeting the underlying biological processes of aging. She uses historical data, economic projections, and biological examples (like the C. elegans worm and long-lived species) to illustrate the massive untapped economic and human potential of extending 'healthspan' rather than just treating terminal conditions. ## Detailed Analysis The speaker begins by establishing a historical context, noting that for thousands of years, most deaths were due to fast incidents like infection or predators, but the 20th century saw a shift where slow, age-related diseases became the dominant cause of death globally. She presents a 2025 US projection showing life expectancy at 79, but the average person receives their first chronic disease diagnosis at age 50, meaning a significant portion of life is spent in declining health. Romanni-Klein emphasizes the vast economic returns of extending healthy lifespan, contrasting the $18B NIH funding for late-stage diseases (lumped into 'Other') with the meager $500M for the biology of aging. She argues that curing all cancers, while noble, only adds about 2.5 years of life expectancy, whereas tackling the aging process itself yields far greater benefits, potentially adding trillions to the US GDP annually based on modeling with her co-authors. She critiques the current research funding cycle, which prioritizes diseases that are both morally urgent and economically promising (like Alzheimer's), often neglecting the root cause—aging—because it is technically difficult and lacks immediate, proven safety/efficacy data. She contrasts this with historical examples of social shifts (like women's suffrage or antibiotic funding) that required overcoming initial resistance due to lacking established moral or institutional frameworks, suggesting that longevity research requires a similar commitment. The ultimate goal, she suggests, is to make 41 the new 40 (or 65 the new 60) by preventing age-related decline rather than just treating its symptoms. ### Historical Context of Mortality - Fast deaths (infection, accidents) prevailed for millennia until the 20th century shift to slow deaths (age-related diseases) - The Black Plague caused a spike in fast deaths around 1400, but scientific advancements shifted the trend toward chronic diseases. ### The Healthspan Gap (US 2025) - Average life expectancy is 79, but the average chronic disease diagnosis occurs at age 50, creating ~29 years of declining healthspan - This gap is widening as life expectancy increases while healthspan remains stagnant. ### Economic Value of Longevity R&D - Curing cancer is estimated to add $80T in economic value to the US over decades, dwarfing the current $500M NIH funding for the biology of aging - Successfully slowing aging by just one year yields a $3T annual gain to the US GDP. ### Critique of Current Research Funding - The funding cycle for diseases like Alzheimer's is problematic because research is funded based on urgency and perceived tractability, not necessarily impact - The speaker suggests this mirrors past resistance to funding antibiotics or women's suffrage because the necessary legal/moral frameworks were not yet in place. ### Solutions to Slow Deaths - The speaker lists five potential solutions, rejecting the unethical option of forcing everyone to die at 65, and favoring treating aging itself over treating diseases one-by-one (which yields smaller gains, e.g., 2.5y for curing all cancers). ### Biological Potential - Research on C. elegans worms showed that altering just two genes (daf-2 and rsks-1) resulted in a lifespan equivalent to a 400-year-old human, indicating aging is malleable. ![Screenshot at 00:27: A timeline graphic showing the prevalence of 'Fast Deaths' \(blue\) historically giving way to 'Slow Deaths' \(pink, age-related diseases\) around the 1900s.](https://ss.rapidrecap.app/screens/kB1IFGYaYXo/00-00-27.jpg) ![Screenshot at 01:30: A bar chart comparing US Healthspan \(blue\) ending around age 50, versus Life Expectancy \(pink\) ending around age 79, illustrating the nearly 30-year health gap.](https://ss.rapidrecap.app/screens/kB1IFGYaYXo/00-01-30.jpg) ![Screenshot at 02:01: A pie chart for 2024 global causes of death showing Age-related diseases \(pink, 75%\) dominating, while Infectious Diseases \(blue, 12%\) are a much smaller slice.](https://ss.rapidrecap.app/screens/kB1IFGYaYXo/00-02-01.jpg) ![Screenshot at 07:36: A bar chart comparing 2023 NIH funding, showing $18B for 'Other \(mostly late-stage diseases of aging\)' versus only $500M for the 'Biology of Aging'.](https://ss.rapidrecap.app/screens/kB1IFGYaYXo/00-07-36.jpg) ![Screenshot at 11:15: A chart titled 'Lifecycle Profiles of U.S. Hourly Earnings' illustrating the typical hump-shaped earnings curve peaking around age 60 and declining thereafter.](https://ss.rapidrecap.app/screens/kB1IFGYaYXo/00-11-15.jpg)